Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy

Radiation Oncology

Pirus Ghadjar³  Daniel M Aebersold³  Steffen Eychmüller¹  Susanne Crowe²  Nikola Cihoric³ 

[1] Center of Palliative Care, Bern University Hospital, and University of Bern, Bern, Switzerland;SAKK Coordinating Center, Bern, Switzerland;Department of Radiation Oncology, Bern University Hospital, and University of Bern, Bern, Switzerland

关键词: Radiotherapy;    Palliative;    Hemostatic;    Bleeding;    Cancer;   

Others  :  1155455
DOI  :  10.1186/1748-717X-7-132

 received in 2012-05-03, accepted in 2012-07-27,  发布年份 2012

【 摘 要 】

Background

This study was performed to evaluate the outcome after hemostatic radiotherapy (RT) of significant bleeding in incurable cancer patients.

Methods

Patients treated by hemostatic RT between November 2006 and February 2010 were retrospectively analyzed. Bleeding was assessed according to the World Health Organization (WHO) scale (grade 0 = no bleeding, 1 = petechial bleeding, 2 = clinically significant bleeding, 3 = bleeding requiring transfusion, 4 = bleeding associated with fatality). The primary endpoint was bleeding at the end of RT. Key secondary endpoints included overall survival (OS) and acute toxicity. The bleeding score before and after RT were compared using the Wilcoxon signed rank test. Time to event endpoints were estimated using the Kaplan Meier method.

Results

Overall 62 patients were analyzed including 1 patient whose benign cause of bleeding was pseudomyxoma peritonei. Median age was 66 (range, 37–93) years. Before RT, bleeding was graded as 2 and 3 in 24 (39%) and 38 (61%) patients, respectively. A median dose of 20 (range, 5–45) Gy of hemostatic RT was applied to the bleeding site. At the end of RT, there was a statistically significant difference in bleeding (p < 0.001); it was graded as 0 (n = 39), 1 (n = 12), 2 (n = 6), 3 (n = 4) and 4 (n = 1). With a median follow-up of 19.3 (range, 0.3-19.3) months, the 6-month OS rate was 43%. Forty patients died (65%); 5 due to bleeding. No grade 3 or above acute toxicity was observed.

Conclusions

Hemostatic RT seems to be a safe and effective treatment for clinically and statistically significantly reducing bleeding in incurable cancer patients.

【 授权许可】

   
2012 Cihoric et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Pereira J, Phan T: Management of bleeding in patients with advanced cancer. Oncologist 2004, 9:561-570.
• [2]Verheij M, Dewit LG, Boomgaard MN, Brinkman HJ, van Mourik JA: Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Willebrand factor. Radiat Res 1994, 137:202-207.
• [3]Yarnold J, Brotons MC: Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol 2010, 97:149-161.
• [4]Bleehen NM, Girling DJ, Machin D, Stephens RJ: A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992, 65:934-941.
• [5]Langendijk JA, Ten Velde GPM, Aaronson NK, De Jong JMA, Muller MJ, Wouters EFM: Quality of life after palliative radiotherapy in non-small cell lung cancer: A prospective study. Int J Radiat Oncol Biol Phys 2000, 47:149-155.
• [6]Halle JS, Rosenman JG, Varia MA, Fowler WC, Walton LA, Currie JL: 1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium. Int J Radiat Oncol Biol Phys 1986, 12:1947-1950.
• [7]Biswal BM, Lal P, Rath GK, Mohanti BK: Hemostatic radiotherapy in carcinoma of the uterine cervix. Int J Gynaecol Obstet 1995, 50:281-285.
• [8]Srinivasan V, Brown CH, Turner AG: A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol) 1994, 6:11-13.
• [9]Din OS, Thanvi N, Ferguson CJ, Kirkbridge P: Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiother Oncol 2009, 93:192-196.
• [10]Hoskin PJ, de Canha SM, Bownes P, Bryant L, Glynne Jones R: High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Radiother Oncol 2004, 73:195-198.
• [11]Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, Wong LC, Leong CN, Zhu M: The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2007, 67:385-388.
• [12]Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47:207-214.
• [13]Yan J, Milosevic M, Fyles A, Manchul L, Kelly V, Levin W: A hypofractionated radiotherapy regimen (0-7-21) for advanced gynaecological cancer patients. Clin Oncol 2011, 23:476-481.